Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice

CI Coleman, WF Peacock, M Antz - Heart, Lung and Circulation, 2018 - Elsevier
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …
被引用次数：8 相关文章

Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German …

CI Coleman, WF Peacock, M Antz - Heart, Lung and Circulation, 2018 - heartlungcirc.org
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …

Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German …

CI Coleman, WF Peacock, M Antz - Heart, Lung & Circulation, 2017 - europepmc.org
Scarce data comparing real-world outcomes between apixaban and vitamin K antagonist
(VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to assess the …

Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German …

CI Coleman, WF Peacock… - Heart, lung & circulation, 2018 - pubmed.ncbi.nlm.nih.gov
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …